Afifah NN, Diantini A, Intania R, Abdulah R, Barliana MI (2020) Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy. Pharmacogenomics and Personalized Medicine: 427–444

Agarwal G, Tulsyan S, Lal P, Mittal B (2016) Generalized multifactor dimensionality reduction (GMDR) analysis of Drug-Metabolizing Enzyme‐Encoding gene polymorphisms May predict treatment outcomes in Indian breast Cancer patients. World J Surg 40:1600–1610

Article  PubMed  Google Scholar 

Akbarali HI, Muchhala KH, Jessup DK, Cheatham S (2022) Chemotherapy induced Gastrointestinal toxicities. Adv Cancer Res 155:131–166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Otaibi TK, Weitzman B, Tahir UA, Asnani A (2022) Genetics of anthracycline-associated cardiotoxicity. Front Cardiovasc Med 9:867873

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F (2020) Cardiovascular toxicity related to Cancer treatment: A pragmatic approach to the American and European Cardio‐Oncology guidelines. J Am Heart Association 9:e018403

Article  CAS  Google Scholar 

Altena R, Bajalica-Lagercrantz S, Papakonstantinou A (2022) Pharmacogenomics for prediction of cardiovascular toxicity: landscape of emerging data in breast Cancer therapies. Cancers 14:4665

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson PM, Thomas SM, Sartoski S, Scott JG, Sobilo K, Bewley S, Salvador LK, Salazar-Abshire M (2021) Strategies to mitigate chemotherapy and radiation toxicities that affect eating. Nutrients 13:4397

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE (2013) PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenetics and Genomics 23

Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL, Neuhausen SL, Senitzer D, Wang S, Forman SJ (2013) Genetic susceptibility to anthracycline-related congestive heart failure in survivors of Haematopoietic cell transplantation. Br J Haematol 163:205–213

Article  CAS  PubMed  PubMed Central  Google Scholar 

Austin Doyle L, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

Article  CAS  PubMed  Google Scholar 

Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A Genome-Wide association study identifies novel loci for Paclitaxel-Induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergh J, Jönsson PE, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol (Stockholm Sweden) 40:253–281

Article  CAS  Google Scholar 

Berkman AM, Hildebrandt MA, Landstrom AP (2021) The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition. Clin Genet 100:132–143

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blanco JG, Sun C-L, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the children’s oncology group. J Clin Oncol 30:1415–1421

Article  CAS  PubMed  Google Scholar 

Borrie AE, Rose FA, Choi Y-H, Perera FE, Read N, Sexton T, Lock M, Vandenberg TA, Hahn K, Younus J (2020) Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. Breast Cancer Res Treat 183:365–372

Article  CAS  PubMed  Google Scholar 

Bosch TM, Meijerman I, Beijnen JH, Schellens JHM (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285

Article  CAS  PubMed  Google Scholar 

Bosó V, Herrero MJ, Santaballa A, Palomar L, Megias JE, de la Cueva H, Rojas L, Marqués MR, Poveda JL, Montalar J, Aliño SF (2014) Snps and taxane toxicity in breast Cancer patients. Pharmacogenomics 15:1845–1858

Article  PubMed  Google Scholar 

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102:1003–1009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR (2020) A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. Int J Cancer 146:2122–2129

Article  CAS  PubMed  Google Scholar 

Brooks DL, Musunuru K (2021) Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair. Cell Stem Cell 28:2039–2040

Article  CAS  PubMed  Google Scholar 

Castro TA, Cohen MC, Rameshwar P (2005) The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exp Metastasis 22:621–628

Article  CAS  PubMed  Google Scholar 

Cecchin E, De Mattia E, Toffoli G (2016) Nuclear receptors and drug metabolism for the personalization of cancer therapy. Expert Opin Drug Metab Toxicol 12:291–306

Article  CAS  PubMed  Google Scholar 

Chen L, Qi H, Zhang L, Li H, Shao J, Chen H, Zhong M, Shi X, Ye T, Li Q (2018) Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients. BMC Cancer 18:1038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, Huang S, Wu X, He W, Song M (2024) Serotonin signalling in cancer: emerging mechanisms and therapeutic opportunities. Clin Translational Med 14:e1750

Article  CAS  Google Scholar 

Christidi E, Huang H, Shafaattalab S, Maillet A, Lin E, Huang K, Laksman Z, Davis MK, Tibbits GF, Brunham LR (2020) Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. Sci Rep 10:10363

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung S, Low S-K, Zembutsu H, Takahashi A, Kubo M, Sasa M, Nakamura Y (2013) A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res 15:1–10

Article  Google Scholar 

Contejean A, Maillard A, Canouï E, Kernéis S, Fantin B, Bouscary D, Parize P, Garcia-Vidal C, Charlier C (2023) Advances in antibacterial treatment of adults with high-risk febrile neutropenia. J Antimicrob Chemother 78:2109–2120

Article  CAS  PubMed  Google Scholar 

Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences 86: 695–698

Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult Cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw J Natl Compr Canc Netw 6:109–118

Article  PubMed  Google Scholar 

Cui L, Huang J, Zhan Y, Qiu N, Jin H, Li J, Huang H, Li H (2021) Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy. Life Sci 276:119392

Article  CAS  PubMed  Google Scholar 

da Costa R, Passos GF, Quintão NLM, Fernandes ES, Maia J, Campos MM, Calixto JB (2020) Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol 177:3127–3146

Article  PubMed  PubMed Central  Google Scholar 

Dahlgren D, Sjöblom M, Hellström PM, Lennernäs H (2021) Chemotherapeutics-Induced intestinal mucositis: pathophysiology and potential treatment strategies. Front Pharmacol 12:681417

Article  CAS